
    
      This study is designed to evaluate the safety of LEM-S401 administered as intradermal
      injection in healthy adult subjects.

      This study will be conducted in 2 parts, Parts A and B. Part A will be a single intradermal
      dose. Overall, 18 subjects will be studied in 3 groups. Each subject will receive LEM-S401 or
      placebo intradermally.

      Part B will be a multiple intradermal dose. Overall, 18 subjects will be divided in 3 groups.
      Each subject will receive LEM-S401 or placebo intradermal injection.
    
  